When Should Levodopa Therapy be Initiated in Patients with Parkinson’s Disease?
- 95 Downloads
Levodopa is available in three forms: immediate-release, orally disintegrating and sustained-release tablets. Levodopa is metabolised in the gastrointestinal tract, kidney and liver by aromatic acid dopa decarboxylase using pyridoxine as a cofactor. Approximately 70–80% of the dose is eliminated in the urine. Central conversion of levodopa to dopamine likely occurs at surviving dopaminergic terminals and at serotonergic and adrenergic nerve terminals that contain decarboxylase. Dopamine is metabolised by catechol-O-methyltransferase and monoamine oxidase. The major metabolites of dopamine are homovanillic acid and dihydroxyphenylacetic acid.
Levodopa remains the most efficacious pharmacological treatment for the symptoms of Parkinson’s disease (PD). Results of current levodopa trials suggest that treatment with levodopa at the onset of disease provides superior motor and functional control compared with dopamine receptor agonists. Moreover, levodopa is generally better tolerated with a lower incidence of gastrointestinal and neuropsychiatric adverse effects. The debate over the role of levodopa in the treatment of PD is fuelled by the results of in vitro studies that show generation of free radicals by levodopa and its toxic effects on cell cultures. Levodopa has also consistently been shown to produce motor fluctuations (in particular dyskinesias) sooner than has been observed in PD patients, especially younger patients, given dopamine agonists initially. However, the cumulative body of knowledge thus far does not show definitive evidence that levodopa is neurotoxic to parkinsonian patients.
In older PD patients with lesser risk of motor fluctuations, levodopa may be used initially, and perhaps solely, in demented PD patients and those at higher risk of developing neuropsychiatric adverse effects. In young parkinsonian patients with mild motor dysfunction, use of levodopa may be delayed or the dosage minimised. However, because of levodopa’s superior efficacy, when a rapid and sustained symptomatic improvement is required because of significant motor disability, levodopa may be used as the first-line agent regardless of age.
No sources of funding were used to assist in the preparation of this review.
Dr Fernandez has served as a consultant, speaker, member of an advisory board or conducted clinical research under contract for Amarin, AstraZeneca, Aventis, Boehringer Ingelheim, Boston Life Sciences, Biogen Idec, Cephalon, Elan, Forest Laboratories, GlaxoSmithKline, Huntington Study Group, Ipsen, Kyowa, Merck KgaA, Merz, MylanBertek, National Parkinson Foundation, Neurotrax, National Institutes of Health/National Institute of Neurological Disorders and Stroke, Novartis, Parkinson Study Group, Solstice, Teva, United Biosource Corporation, Valeant and Vernalis. The other authors have no potential conflicts of interest that are directly relevant to the content of this review.
- 3.Barbeau A, Sourkes T, Murphy G. Les catecholamines dans la maladie de Parkinson. In: DeAjuriaguerra J, editor. Monoamines et systeme nerveux central. Paris: Masson, 1962: 925–7Google Scholar
- 10.Product Information: Sinemet®, carbidopa/levodopa. Whitehouse Station (NJ): Merck and Co., 2002Google Scholar
- 19.Product Information: Parcopa™ orally disintegrating tablets, carbidopa-levodopa orally disintegrating tablets. Milwaukee (WI): Schwarz Pharma, 2003Google Scholar
- 25.Product Information: Comtan®, entacapone. East Hanover (NJ): Novartis Pharmaceutical Corporation, 2000Google Scholar
- 27.Product Information: Stalevo™ (carbidopa, levodopa and entacapone) tablets. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2003Google Scholar
- 28.Product Information: Comtan®, entacapone. East Hanover (NJ): Novartis Pharmaceutical Corporation, 2000Google Scholar
- 29.Product Information: TASMAR® tablets, tolcapone tablets. Costa Mesa (CA): Valeant Pharmaceuticals, Inc., 2006Google Scholar
- 54.Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287(13): 1653–61Google Scholar
- 76.Saint-Hilaire MH, Feldman RG. The ‘on-off’ phenomenon in Parkinson’s disease. In: Joseph AB, Young RR, editors. Movement disorders in neurology and neuropsychiatry. Boston (MA): Blackwell Scientific Publications, 1999: 180–4Google Scholar